-+ 0.00%
-+ 0.00%
-+ 0.00%

ATOSSA THERAPEUTICS ANNOUNCES ASCO 2026 ABSTRACTS HIGHLIGHTING (Z)-ENDOXIFEN ACTIVITY ACROSS ESR1 MUTATIONS AND ONGOING EVANGELINE PHASE 2 TRIAL

Reuters·05/27/2026 12:30:05

Please log in to view news